Erastin: Benchmark Ferroptosis Inducer for Cancer Biology

Executive Summary: Erastin is a selective inducer of ferroptosis, characterized by iron-dependent, non-apoptotic cell death, and is widely used to dissect oxidative stress mechanisms in tumor biology. The molecule targets RAS/BRAF-mutant tumor cells by inhibiting the cystine/glutamate antiporter system Xc⁻, leading to depletion of intracellular glutathione and lethal reactive oxygen species (ROS) accumulation (APExBIO product info). Its specificity has been validated in cell-based assays, notably using HT-1080 fibrosarcoma cells at 10 μM for 24 hours. Erastin is a preferred tool for investigating redox vulnerabilities in cancer and for benchmarking iron-dependent cell death pathways (see discussion). Reliable storage and solution stability parameters are critical for experimental reproducibility.

Biological Rationale

Ferroptosis is an iron-dependent, non-apoptotic form of cell death distinguished by the accumulation of lipid peroxides and ROS, fundamentally diverging from apoptosis, necrosis, or autophagy (Yang et al., 2024). Tumor cells with oncogenic RAS or BRAF mutations display increased sensitivity to ferroptosis due to altered redox metabolism. Therapies targeting ferroptosis have emerged as potential interventions in cancer biology research, given their ability to exploit metabolic vulnerabilities in malignant cells. Erastin acts as a small-molecule trigger for ferroptosis, making it an essential tool for mechanistic studies and drug discovery efforts in this area (see comparative review).

Mechanism of Action of Erastin

Erastin (chemical name: 2-[1-[4-[2-(4-chlorophenoxy)acetyl]piperazin-1-yl]ethyl]-3-(2-ethoxyphenyl)quinazolin-4-one, MW 547.04) disrupts cellular redox balance by binding to and modulating voltage-dependent anion channels (VDAC) on the mitochondrial membrane (APExBIO). It inhibits the cystine/glutamate antiporter system Xc⁻, which normally imports cystine in exchange for glutamate. Inhibition of system Xc⁻ reduces intracellular cystine and glutathione (GSH) levels, disabling the cell's antioxidant defenses and promoting the accumulation of lethal ROS (Yang et al., 2024). This cascade culminates in ferroptotic cell death, particularly in cells with compromised redox homeostasis, such as those bearing RAS or BRAF mutations.

Evidence & Benchmarks

• Erastin induces ferroptosis in engineered human tumor cells and HT-1080 fibrosarcoma cells at 10 μM for 24 hours, causing a marked reduction in cell viability and increased ROS production (product documentation).
• Ferroptotic cell death induced by Erastin is iron-dependent and morphologically distinct from apoptosis and necrosis, confirmed by mitochondrial shrinkage and increased membrane density (Yang et al., 2024).
• In vitro studies have demonstrated that Erastin-induced ferroptosis is inhibited by iron chelators and lipophilic antioxidants, supporting its specificity as a ferroptosis inducer (see functional review).
• Erastin is insoluble in water and ethanol but dissolves in DMSO at ≥10.92 mg/mL with gentle warming, ensuring compatibility with standard cell culture assays (APExBIO).
• Freshly prepared Erastin solutions are recommended for maximum activity, with DMSO stock solutions stable at -20°C for several months (APExBIO).

This article extends the practical guidance in "Erastin (SKU B1524): Practical Solutions for Ferroptosis Assays" by providing structured evidence claims and explicit protocol parameters for reproducible results.

Applications, Limits & Misconceptions

Erastin is primarily used in cancer biology and ferroptosis research to investigate redox-dependent cell death mechanisms, particularly in RAS/BRAF-mutated tumor contexts. Its selectivity enables detailed analysis of oxidative stress pathways and evaluation of candidate ferroptosis inhibitors or neuroprotective agents (Yang et al., 2024). Erastin's role as a benchmark ferroptosis inducer makes it a reference compound for assay development and screening workflows.

Common Pitfalls or Misconceptions

• Erastin is not effective in cell types lacking system Xc⁻ expression or with robust alternative cystine import mechanisms; efficacy is context-dependent.
• It should not be used to model apoptotic or necrotic pathways, as its effects are specific to ferroptosis.
• Erastin stock solutions are unstable at room temperature; using old or improperly stored solutions may result in diminished activity.
• Solubility in DMSO is required; attempting dissolution in water or ethanol leads to precipitation and unreliable dosing.
• Interpretation of in vivo effects requires caution, as Erastin's pharmacokinetics and bioavailability are not fully characterized for systemic administration.

This article clarifies mechanistic boundaries compared to "Scenario-Driven Solutions in Ferroptosis Research" by specifying cell-type limitations and solution handling protocols.

Workflow Integration & Parameters

For reproducible oxidative stress assays and ferroptosis induction, Erastin (SKU B1524, APExBIO) is applied as follows:

Protocol Parameters

• Cell line selection: Use RAS- or BRAF-mutant tumor cells (e.g., HT-1080 fibrosarcoma) for optimal sensitivity to ferroptosis.
• Compound preparation: Dissolve Erastin in DMSO at ≥10.92 mg/mL with gentle warming; prepare fresh before use.
• Working concentration: 10 μM Erastin for 24 hours is standard for robust ferroptosis induction in vitro.
• Storage conditions: Stock solutions can be stored at -20°C for several months; ship with blue ice to preserve integrity.
• Assay controls: Include iron chelators (e.g., deferoxamine) and lipophilic antioxidants (e.g., ferrostatin-1) to confirm ferroptosis specificity in cell death readouts.

For practical workflow troubleshooting and scenario-based guidance, see "Practical Solutions for Ferroptosis Assays", which this article augments by providing protocol clarity and explicit vendor recommendations.

Conclusion & Outlook

Erastin remains a gold-standard tool for dissecting ferroptosis in cancer biology and oxidative stress research. Its specificity for RAS/BRAF-mutant tumor cells, well-characterized mechanism, and compatibility with standard assays underpin its value in both discovery and translational workflows. As highlighted in recent studies, including the use of Erastin to model ferroptosis in vitro and test neuroprotective strategies with agents like fisetin (Yang et al., 2024), the compound enables rigorous investigation of redox-regulated cell death and resistance mechanisms. Ongoing research will further clarify its in vivo applicability and extend its utility in medicinal chemistry and therapeutic development.

For detailed technical specifications and ordering, consult the APExBIO Erastin product page. This article provides a structured, evidence-driven resource beyond the scope of "Erastin: A Ferroptosis Inducer Transforming Cancer Biology" by integrating explicit protocol and handling recommendations for laboratory end-users.